Abstract
Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations. Thymogen therapy was conducive to normalization of lymphocyte counts, absolute counts of T and B lymphocytes, increase of T lymphocyte functional activity. The drug is characterized by a desensitizing effect and induces no complications. Marked clinical effect recommends the immunomodulator thymogen for combined therapy of patients with inflammatory diseases of the uterus and its appendages.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Adjuvants, Immunologic / administration & dosage*
-
Adult
-
Anti-Inflammatory Agents / administration & dosage
-
Bacterial Infections / drug therapy*
-
Bacterial Infections / etiology
-
Bacterial Infections / immunology
-
Chronic Disease
-
Dipeptides*
-
Drug Therapy, Combination
-
Endometritis / drug therapy*
-
Endometritis / etiology
-
Endometritis / immunology
-
Female
-
Humans
-
Lymphopenia / complications
-
Lymphopenia / drug therapy
-
Middle Aged
-
Pelvic Inflammatory Disease / drug therapy*
-
Pelvic Inflammatory Disease / etiology
-
Pelvic Inflammatory Disease / immunology
-
Peptides / administration & dosage*
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
Substances
-
Adjuvants, Immunologic
-
Anti-Inflammatory Agents
-
Dipeptides
-
Peptides
-
thymogen